Table 1.
Clinical characteristics of CML patients
Characteristics (n = 93)Median (range)
Age (yr) 60.1 (23–85) 
Male/female 58/35 
Sokal risk (low/int./high) 59/24/4 
EUTOS risk (low/high) 73/5 
Prior IFN-α (+/−) 19/74 
CML duration (mo) 84.8 (13.2–229.4) 
Duration of IM treatment (mo) 75.7 (12.6–122.4) 
Actual daily IM dose (mg/d) 400 (66.7–400) 
Median time to CCyR (mo) 
From diagnosis to CCyR 6.6 (1–103.3) 
From IM therapy to CCyR 5.3 (0.5–76.7) 
Median time to MMR (mo) 
From diagnosis to MMR 19.5 (4.4–185.6) 
From IM therapy to MMR 17.0 (3.2–93.9) 

CCyR, complete cytogenetic response; EUTOS, European Treatment and Outcome Study; IM, imatinib; int., intermediate; MMR, major molecular response.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Please sign in to your personal account to gift article access.

Register

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.

Gift articles remaining: --

Gift article access

As a benefit of your subscription, you can share temporary access to restricted articles.

Each link will stop working after 30 days or 10 uses.

You have reached the limit of 10 links within a 30 day period.

Sharing Unavailable

Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.